# Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

> **NCT02694224** · PHASE2 · UNKNOWN · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** vismodegib
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02694224
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694224, "Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02694224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*